{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-23-291705","form_type":"8-K","ticker":"ACRV","cik":"0001781174","company_name":"Acrivon Therapeutics, Inc.","filed_at":"2023-12-08T23:59:59+00:00","discovered_at":"2026-05-14T18:03:30.398531+00:00","generated_at":"2026-06-07T15:40:18.042267+00:00","sec_items":["1.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"confidence":"high","headline":"Acrivon expands Akoya companion diagnostic deal to $17.3M for ACR-368 OncoSignature test","bullets":["Third Amendment with Akoya increases total milestone payments to $17.3M through FDA pre-market approval for multiple indications.","$3.8M in milestones already achieved and paid to date; cash runway unchanged from Nov 2023 10-Q.","Expanded scope of work covers development of ACR-368 companion diagnostic test across multiple indications."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-23-291705","json":"https://secwatch.observer/filing/0001193125-23-291705.json","markdown":"https://secwatch.observer/filing/0001193125-23-291705.md","text":"https://secwatch.observer/filing/0001193125-23-291705.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1781174/000119312523291705/0001193125-23-291705-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1781174/000119312523291705/d608194d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-07T15:40:18.042267+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"859d64739c3076f40869b3b6dfb7009c57efa19c","claim":"Acrivon Therapeutics, Inc. amended OncoSignature Diagnostic Agreement with Akoya Biosciences, Inc. valued at $17,300,000 (effective 2023-12-04).","evidence_excerpt":"On December 4, 2023, Acrivon Therapeutics, Inc. (the “Company”) entered into a Third Amendment to the OncoSignature Diagnostic Agreement (the “Third Amendment”) with Akoya Biosciences, Inc. (“Akoya”) for the development of the ACR-368 OncoSignature companion diagnostic test.","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1781174/000119312523291705/0001193125-23-291705-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"amendment"},{"label":"Agreement","value":"collaboration"},{"label":"Counterparty","value":"Akoya Biosciences, Inc."},{"label":"Value","value":"$17,300,000"},{"label":"Effective","value":"2023-12-04"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}